219 related articles for article (PubMed ID: 8998122)
1. Risk of contralateral breast cancer among women with carcinoma in situ of the breast.
Habel LA; Moe RE; Daling JR; Holte S; Rossing MA; Weiss NS
Ann Surg; 1997 Jan; 225(1):69-75. PubMed ID: 8998122
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological survey of preinvasive breast cancer.
Vandenbroucke A; Bourdon C
Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():3-10. PubMed ID: 8298449
[TBL] [Abstract][Full Text] [Related]
3. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
4. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
[TBL] [Abstract][Full Text] [Related]
5. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry.
Claus EB; Stowe M; Carter D; Holford T
Breast; 2003 Dec; 12(6):451-6. PubMed ID: 14659121
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.
Ottesen GL; Graversen HP; Blichert-Toft M; Christensen IJ; Andersen JA
Breast Cancer Res Treat; 2000 Aug; 62(3):197-210. PubMed ID: 11072784
[TBL] [Abstract][Full Text] [Related]
7. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
8. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
9. The Pathologic Finding of Combined Lobular Carcinoma
Jean-Louis CJ; Masdon J; Smith B; Battles O; Dale P
Am Surg; 2017 May; 83(5):482-485. PubMed ID: 28541858
[TBL] [Abstract][Full Text] [Related]
10. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
11. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ.
Ringberg A; Palmer B; Linell F; Rychterova V; Ljungberg O
Eur J Surg Oncol; 1991 Feb; 17(1):20-9. PubMed ID: 1847343
[TBL] [Abstract][Full Text] [Related]
12. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.
Mullooly M; Khodr ZG; Dallal CM; Nyante SJ; Sherman ME; Falk R; Liao LM; Love J; Brinton LA; Gierach GL
Am J Epidemiol; 2017 Dec; 186(12):1329-1340. PubMed ID: 28637226
[TBL] [Abstract][Full Text] [Related]
13. Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?
Minami CA; Zabor EC; Gilbert E; Newman A; Park A; Jochelson MS; King TA; Pilewskie ML
Ann Surg Oncol; 2020 Jun; 27(6):1844-1851. PubMed ID: 31898097
[TBL] [Abstract][Full Text] [Related]
14. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.
Li CI; Daling JR; Malone KE
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1008-11. PubMed ID: 15824180
[TBL] [Abstract][Full Text] [Related]
15. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.
Wong SM; King T; Boileau JF; Barry WT; Golshan M
Ann Surg Oncol; 2017 Sep; 24(9):2509-2517. PubMed ID: 28455673
[TBL] [Abstract][Full Text] [Related]
16. Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up.
Ringberg A; Andersson I; Aspegren K; Linell F
Eur J Surg Oncol; 1991 Oct; 17(5):466-76. PubMed ID: 1657650
[TBL] [Abstract][Full Text] [Related]
17. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Claus EB; Stowe M; Carter D
Breast Cancer Res Treat; 2003 Mar; 78(1):7-15. PubMed ID: 12611452
[TBL] [Abstract][Full Text] [Related]
18. Trends of in situ carcinoma of the breast in Vaud, Switzerland.
Levi F; Te VC; Randimbison L; La Vecchia C
Eur J Cancer; 1997 May; 33(6):903-6. PubMed ID: 9291813
[TBL] [Abstract][Full Text] [Related]
19. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings.
Liberman L; Sama M; Susnik B; Rosen PP; LaTrenta LR; Morris EA; Abramson AF; Dershaw DD
AJR Am J Roentgenol; 1999 Aug; 173(2):291-9. PubMed ID: 10430122
[TBL] [Abstract][Full Text] [Related]
20. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group.
Ottesen GL; Graversen HP; Blichert-Toft M; Zedeler K; Andersen JA
Am J Surg Pathol; 1993 Jan; 17(1):14-21. PubMed ID: 8383466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
